文献速递神经核医学肿瘤 PET/CT

临床前阿尔茨海默病中脑代谢下降的淀粉样蛋白与tau蛋白特征

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-02

在120例认知正常老年人中,以2年[18F]FDG脑葡萄糖代谢下降为结局,分析[18F]florbetapir Aβ PET与脑脊液磷酸化tau阈值。Aβ与磷酸化tau同时高于各自异常阈值一个标准差以上最能预测临床前AD的代谢下降;采用这些阈值,检测2年25%药物效应仅需约100人。

要点

  • Aβ PET标准化摄取值比与磷酸化tau同时高于各自异常阈值一个标准差以上,是临床前AD代谢下降的最佳预测指标。
  • 采用上述阈值,2年25%药物效应对FDG摄取下降的试验约需100人即可达到80%把握度。
  • 联合Aβ与tau阈值可作为预测 imminent 神经变性的替代框架,用于评估疾病修饰治疗对FDG下降的效果。

核心结论

  • 联合Aβ与tau阈值可预测临床前AD个体即将发生的神经变性,并作为在典型2年临床试验期内检验疾病修饰治疗对[18F]FDG摄取下降效果的高统计效力替代框架。

研究设计与样本

  • 在120例认知正常老年人中开展阈值分析,将2年[18F]FDG脑葡萄糖代谢下降建模为[18F]florbetapir Aβ PET与脑脊液磷酸化tau生物标志物阈值的函数。
  • 另采用新的体素级分析框架,计算在脑内每个体素检测2年FDG摄取变化中估计25%药物效应、80%把握度所需的样本量。

主要发现

  • [18F]florbetapir标准化摄取值比与磷酸化tau水平同时高于各自生物标志物异常阈值一个标准差以上,是临床前AD个体代谢下降的最佳预测指标。
  • 采用这些阈值的临床试验,检测2年AD相关代谢下降的25%药物效应仅需约100人。

关键数值与推荐

  • Aβ PET标准化摄取值比与磷酸化tau水平同时高于各自异常阈值一个标准差以上,为最佳预测代谢下降的联合阈值。
  • 采用上述阈值时,检测2年25%药物效应对FDG摄取下降的试验约需100人(80%把握度)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to determine the amyloid (Aβ) and tau biomarker levels associated with imminent Alzheimer's disease (AD) - related metabolic decline in cognitively normal individuals. METHODS: A threshold analysis was performed in 120 cognitively normal elderly individuals by modelling 2-year declines in brain glucose metabolism measured with [18F]fluorodeoxyglucose ([18F]FDG) as a function of [18F]florbetapir Aβ positron emission tomography (PET) and cerebrospinal fluid phosphorylated tau biomarker thresholds. Additionally, using a novel voxel-wise analytical framework, we determined the sample sizes needed to test an estimated 25% drugeffect with 80% of power on changes in FDG uptake over 2 years at every brain voxel. RESULTS: The combination of [18F]florbetapir standardized uptake value ratios and phosphorylated-tau levels more than one standard deviation higher than their respective thresholds for biomarker abnormality was the best predictor of metabolic decline in individuals with preclinical AD. We also found that a clinical trial using these thresholds would require as few as 100 individuals to test a 25% drug effect on AD-related metabolic decline over 2 years. CONCLUSIONS: These results highlight the new concept that combined Aβ and tau thresholds can predict imminent neurodegeneration as an alternative framework with a high statistical power for testing the effect of disease-modifying therapies on [18F]FDG uptake decline over a typical 2-year clinical trial period in individuals with preclinical AD.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pascoal TA, Mathotaarachchi S, Shin M, et al. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2018. PMID: 29396637. doi:10.1007/s00259-018-3933-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。